Cancer clinical trials in the region Île-de-France

686 currently recruiting clinical trials
Region Île-de-France
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03175224 #2024-514542-37-00
Cohortes C, D
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
5 recruiting sites
Apollomics
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT03175224 #2024-514542-37-00
Cohorte F
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
ALK BRAF EGFR KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2 Brain tumors / Central nervous system tumors #NCT03175224 #2024-514542-37-00
Cohorte E
Required genetic anomalies
MET
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
BRAF EGFR NTRK-1/2/3 ALK KRAS G12C KRAS non G12C RET ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2 Endometrial cancer #NCT05548296 #2025-524542-10-00
Bras 3 et 4
Required histologic sub types
Serous adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Acrivon Therapeutics
Phase 2 Multiple myeloma #NCT07227311 #2025-523117-28-00
Cohorte BVd (Belantamab mafodotin + Bortezomib + Dexamethasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1 2
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
3 recruiting sites
GlaxoSmithKline
Phase 2 Multiple myeloma #NCT07227311 #2025-523117-28-00
Cohorte BKd (Belantamab mafodotin + Carfilzomib + dexaméthasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1 2
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
2 recruiting sites
GlaxoSmithKline
Phase 2 Multiple myeloma #NCT07227311 #2025-523117-28-00
Cohorte BPd (Belantamab + Pomalidomide + Dexamethasone))
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1 2
Required previous treatments
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
2 recruiting sites
GlaxoSmithKline
Phase 2 Chronic myeloid leukemia (CML) #NCT06514534 #2024-516049-38-00
Required disease stage
Chronic phase Accelerated phase
Required genetic anomalies
T315I
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
ATP pocket inhibitor
Excluded previous treatments
Systemic Treatment-Naive Allosteric inhibitor
7 recruiting sites
Novartis
Phase 2 Stomach and esophageal cancer #NCT06846346 #2025-520694-39-00
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
Claudin 18.2 HER2 MSI/dMMR
7 recruiting sites
UNICANCER
Phase 2 Lymphoma #NCT06271057 #2023-506705-20-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma Primary mediastinal lymphoma Indolent transformed lymphoma
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
13 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)